The RAB27A effector SYTL5 regulates mitophagy and mitochondrial metabolism

Reviewer #1 (Public review):

Summary:

In this study, Ana Lapao et al. investigated the roles of Rab27 effector SYTL5 in cellular membrane trafficking pathways. The authors found that SYTL5 localizes to mitochondria in a Rab27A-dependent manner. They demonstrated that SYTL5-Rab27A positive vesicles containing mitochondrial material are formed under hypoxic conditions, thus they speculate that SYTL5 and Rab27A play roles in mitophagy. They also found that both SYTL5 and Rab27A are important for normal mitochondrial respiration. Cells lacking SYTL5 undergo a shift from mitochondrial oxygen consumption to glycolysis which is a common process known as the Warburg effect in cancer cells. Based on the cancer patient database, the author noticed that low SYTL5 expression is related to reduced survival for adrenocortical carcinoma patients, indicating SYTL5 could be a negative regulator of the Warburg effect and potentially tumorigenesis.

Strengths:

The authors take advantage of multiple techniques and novel methods to perform the experiments.

(1) Live-cell imaging revealed that stably inducible expression of SYTL5 co-localized with filamentous structures positive for mitochondria. This result was further confirmed by using correlative light and EM (CLEM) analysis and western blotting from purified mitochondrial fraction.

(2) In order to investigate whether SYTL5 and RAB27A are required for mitophagy in hypoxic conditions, two established mitophagy reporter U2OS cell lines were used to analyze the autophagic flux.

Weaknesses:

This study revealed a potential function of SYTL5 in mitophagy and mitochondrial metabolism. However, the mechanistic evidence that establishes the relationship between SYTL5/Rab27A and mitophagy is insufficient. The involvement of SYTL5 in ACC needs more investigation. Furthermore, images and results supporting the major conclusions need to be improved.

Reviewer #2 (Public review):

Summary:

The authors provide convincing evidence that Rab27 and STYL5 work together to regulate mitochondrial activity and homeostasis.

Strengths:

The development of models that allow the function to be dissected, and the rigorous approach and testing of mitochondrial activity

Weaknesses:

There may be unknown redundancies in both pathways in which Rab27 and SYTL5 are working which could confound the interpretation of the results.

Suggestions for revision:

Given that Rab27A and SYTL5 are members of protein families it would be important to exclude any possible functional redundancies coming from Rab27B expression or one of the other SYTL family members. For Rab27 this would be straightforward to test in the assays shown in Figure 4 and Supplementary Figure 5. For SYTL5 it might be sufficient to include some discussion about this possibility.

Suggestions for Discussion:

Both Rab27A and STYL5 localize to other membranes, including the endolysosomal compartments. How do the authors envisage the mechanism or cellular modifications that allow these proteins, either individually or in complex to function also to regulate mitochondrial function? It would be interesting to have some views.

Reviewer #3 (Public review):

Summary:

In the manuscript by Lapao et al., the authors uncover a role for the RAB27A effector protein SYTL5 in regulating mitochondrial function and turnover. The authors find that SYTL5 localizes to mitochondria in a RAB27A-dependent way and that loss of SYTL5 (or RAB27A) impairs lysosomal turnover of an inner mitochondrial membrane mitophagy reporter but not a matrix-based one. As the authors see no co-localization of GFP/mScarlet tagged versions of SYTL5 or RAB27A with LC3 or p62, they propose that lysosomal turnover is independent of the conventional autophagy machinery. Finally, the authors go on to show that loss of SYTL5 impacts mitochondrial respiration and ECAR and as such may influence the Warburg effect and tumorigenesis. Of relevance here, the authors go on to show that SYTL5 expression is reduced in adrenocortical carcinomas and this correlates with reduced survival rates.

Strengths:

There are clearly interesting and new findings here that will be relevant to those following mitochondrial function, the endocytic pathway, and cancer metabolism.

Weaknesses:

The data feel somewhat preliminary in that the conclusions rely on exogenously expressed proteins and reporters, which do not always align.

As the authors note there are no commercially available antibodies that recognize endogenous SYTL5, hence they have had to stably express GFP-tagged versions. However, it appears that the level of expression dictates co-localization from the examples the authors give (though it is hard to tell as there is a lack of any kind of quantitation for all the fluorescent figures). Therefore, the authors may wish to generate an antibody themselves or tag the endogenous protein using CRISPR.

In relation to quantitation, the authors found that SYTL5 localizes to multiple compartments or potentially a few compartments that are positive for multiple markers. Some quantitation here would be very useful as it might inform on function.

The authors find that upon hypoxia/hypoxia-like conditions that punctate structures of SYTL5 and RAB27A form that are positive for Mitotracker, and that a very specific mitophagy assay based on pSu9-Halo system is impaired by siRNA of SYTL5/RAB27A, but another, distinct mitophagy assay (Matrix EGFP-mCherry) shows no change. I think this work would strongly benefit from some measurements with endogenous mitochondrial proteins, both via immunofluorescence and western blot-based flux assays.

A really interesting aspect is the apparent independence of this mitophagy pathway on the conventional autophagy machinery. However, this is only based on a lack of co-localization between p62 or LC3 with LAMP1 and GFP/mScarlet tagged SYTL5/RAB27A. However, I would not expect them to greatly colocalize in lysosomes as both the p62 and LC3 will become rapidly degraded, while the eGFP and mScarlet tags are relatively resistant to lysosomal hydrolysis. -/+ a lysosome inhibitor might help here and ideally, the functional mitophagy assays should be repeated in autophagy KOs.

The link to tumorigenesis and cancer survival is very interesting but it is not clear if this is due to the mitochondrially-related aspects of SYTL5 and RAB27A. For example, increased ECAR is seen in the SYTL5 KO cells but not in the RAB27A KO cells (Fig.5D), implying that mitochondrial localization of SYTL5 is not required for the ECAR effect. More work to strengthen the link between the two sections in the paper would help with future directions and impact with respect to future cancer treatment avenues to explore.